
    
      Patients are randomized to receive 1 of 3 study regimens: Group A - Saquinavir (SQV) soft gel
      capsules (sgc) plus 2 reverse transcriptase inhibitors (RTIs), Group B - SQV sgc plus
      delavirdine plus RTI, and Group C - SQV sgc plus nelfinavir plus RTI (or SQV sgc plus
      ritonavir plus 2 RTIs).
    
  